Literature DB >> 29914964

In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.

A Van Dalem1, M Herpol2, F Echahidi2, C Peeters3, I Wybo2, E De Wachter4, P Vandamme3, D Piérard2.   

Abstract

We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole. Eighty-one and 63% of all BCC strains were susceptible to ceftazidime-avibactam and ceftolozane-tazobactam, respectively. For temocillin, ceftazidime, piperacillin-tazobactam, and meropenem, at least 50% of the strains were susceptible. B. stabilis seems to be more resistant than other BCC species.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Burkholderia cepacia complex; ceftazidime-avibactam; ceftolozane-tazobactam; cystic fibrosis; in vitro susceptibility

Mesh：

Substances：

Year:  2018        PMID： 29914964      PMCID： PMC6125557          DOI： 10.1128/AAC.00590-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

1.  Clonality and Antimicrobial Susceptibility of Burkholderia cepacia complex Isolates Collected from Cystic Fibrosis Patients during 1998-2013 in Bern, Switzerland.

Authors:  Agnese Lupo; Enver Isis; Regula Tinguely; Andrea Endimiani
Journal:  New Microbiol       Date:  2015-04-29       Impact factor: 2.479

2.  Interpretive criteria for temocillin disk diffusion susceptibility testing.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones
Journal:  Eur J Clin Microbiol       Date:  1985-02       Impact factor: 3.267

3.  In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides.

Authors:  Agatha N Jassem; James E A Zlosnik; Deborah A Henry; Robert E W Hancock; Robert K Ernst; David P Speert
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

4.  In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.

Authors:  Shazad Mushtaq; Marina Warner; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2010-08-26       Impact factor: 5.790

5.  Temocillin in the treatment of Burkholderia cepacia infection in cystic fibrosis.

Authors:  Anastasios Lekkas; Khin M Gyi; Margaret E Hodson
Journal:  J Cyst Fibros       Date:  2006-05       Impact factor: 5.482

Review 6.  Antibiotic resistance in Burkholderia species.

Authors:  Katherine A Rhodes; Herbert P Schweizer
Journal:  Drug Resist Updat       Date:  2016-07-30       Impact factor: 18.500

7.  Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance.

Authors:  J L Burns; C D Wadsworth; J J Barry; C P Goodall
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

8.  Cell Wall Recycling-Linked Coregulation of AmpC and PenB β-Lactamases through ampD Mutations in Burkholderia cenocepacia.

Authors:  Junghyun Hwang; Heenam Stanley Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

9.  In Vitro Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.

Authors:  Dale M Mazer; Carol Young; Linda M Kalikin; Theodore Spilker; John J LiPuma
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 10.  Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.

Authors:  Alex Horsley; Andrew M Jones; Robert Lord
Journal:  Cochrane Database Syst Rev       Date:  2016-01-20
View more
  8 in total

1.  Resurrecting Old β-Lactams: Potent Inhibitory Activity of Temocillin against Multidrug-Resistant Burkholderia Species Isolates from the United States.

Authors:  Elise T Zeiser; Scott A Becka; Melissa D Barnes; Magdalena A Taracila; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.

Authors:  Elise T Zeiser; Scott A Becka; Brigid M Wilson; Melissa D Barnes; John J LiPuma; Krisztina M Papp-Wallace
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

3.  In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Authors:  Krisztina M Papp-Wallace; Adam B Shapiro; Scott A Becka; Elise T Zeiser; John J LiPuma; Douglas J Lane; Rekha G Panchal; John P Mueller; John P O'Donnell; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  Burkholderia ubonensis High-Level Tetracycline Resistance Is Due to Efflux Pump Synergy Involving a Novel TetA(64) Resistance Determinant.

Authors:  Nawarat Somprasong; Carina M Hall; Jessica R Webb; Jason W Sahl; David M Wagner; Paul Keim; Bart J Currie; Herbert P Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

5.  The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States.

Authors:  Scott A Becka; Elise T Zeiser; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antibiotics (Basel)       Date:  2022-05-17

6.  Genomics of an endemic cystic fibrosis Burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity.

Authors:  Cédric Lood; Charlotte Peeters; Quentin Lamy-Besnier; Jeroen Wagemans; Daniel De Vos; Marijke Proesmans; Jean-Paul Pirnay; Fedoua Echahidi; Denis Piérard; Matthieu Thimmesch; Anca Boeras; Katrien Lagrou; Evelien De Canck; Elke De Wachter; Vera van Noort; Rob Lavigne; Peter Vandamme
Journal:  PLoS Pathog       Date:  2021-03-15       Impact factor: 6.823

7.  Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.

Authors:  Scott A Becka; Elise T Zeiser; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

8.  Atypical Burkholderia Cepacia Resistance to Ceftazidime/Avibactam and Co-trimoxazole: A Case of Open Wound Contamination and Persistent Bacteremia.

Authors:  Fidelis Uwumiro; Ehizogie Edigin; Victory Okpujie
Journal:  Cureus       Date:  2021-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.